Article
Hematology
Juan Jose Rodriguez-Sevilla, Concepcion Fernandez-Rodriguez, Leyre Bento, Ramon Diez-Feijoo, Sergio Pinzon, Joan Gibert, Lierni Fernandez-Ibarrondo, Marta Lafuente, Ana Ferrer, Blanca Sanchez-Gonzalez, Eva Gimeno, Juan Sainz, Rafael Ramos, Juan F. Garcia, Lluis Colomo, Beatriz Bellosillo, Antonio Gutierrez, Antonio Salar
Summary: Four clinical or clinicogenetic-risk models were explored in patients with symptomatic FL who received frontline immunochemotherapy. The FLIPI remains the clinical risk score with higher discrimination in patients with advanced FL treated with immunochemotherapy, but the performance of the m7-FLIPI should be further investigated in patients treated with R-B.
Article
Oncology
Yaxiao Lu, Jingwei Yu, Wenchen Gong, Liping Su, Xiuhua Sun, Ou Bai, Hui Zhou, Xue Guan, Tingting Zhang, Lanfang Li, Lihua Qiu, Zhengzi Qian, Shiyong Zhou, Bin Meng, Xiubao Ren, Xianhuo Wang, Huilai Zhang
Summary: The study aimed to evaluate the prognostic value of peripheral blood T lymphocyte subsets in FL patients and develop a predictive model (ICPI) for PFS. The ICPI demonstrated improved prognostic performance and could guide personalized therapy for patients treated with R-CHOP/CHOP chemotherapy.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Zhi-Qiao Liu, Ya-Nan Zhao, Yi-Shan Wu, Bao-Yu Zhang, En-Ni Chen, Qing-He Peng, Su-Ming Xiao, Dian Ouyang, Fang-Yun Xie, Pu-Yun Ouyang
Summary: This study aimed to investigate the benefit of locoregional radiotherapy in de novo metastatic nasopharyngeal carcinoma in the era of immunotherapy and identify the patients who can benefit from radiotherapy. The results showed that immunochemotherapy plus subsequent radiotherapy prolonged the survival of patients, especially those with oligometastases, low EBV DNA levels, and complete or partial relapse after immunochemotherapy.
Article
Health Care Sciences & Services
Isabel Cornell, Ayisha Al Busaidi, Stephen Wastling, Mustafa Anjari, Kate Cwynarski, Christopher P. Fox, Nicolas Martinez-Calle, Edward Poynton, John Maynard, Steffi C. Thust
Summary: By studying the changes in tumour volume and apparent diffusion coefficient (ADC) measurements in PCNSL patients treated with MATRix chemotherapy, we found that ADC and T1CE metrics are potential biomarkers for predicting treatment response. Response after four cycles of chemotherapy differed from response after two cycles. Baseline ADC and T1CE metrics were predictive of MATRix treatment response. Standard interim response assessment (after two cycles) did not reliably predict early disease progression.
JOURNAL OF PERSONALIZED MEDICINE
(2023)
Article
Medicine, General & Internal
Carole Durot, Eric Durot, Sebastien Mule, David Morland, Francois Godard, Anne Quinquenel, Alain Delmer, Philippe Soyer, Christine Hoeffel
Summary: The purpose of this study was to determine whether texture features on pretreatment unenhanced CT images derived from 18F-FDG PET/CT can predict survival outcomes in patients with high-tumor-burden follicular lymphoma treated with immunochemotherapy and rituximab maintenance. The study found that skewness at a fine texture scale and kurtosis without filtration were independent predictors of progression-free survival and time to next treatment. The results suggest that pretreatment unenhanced CT texture analysis-derived skewness and kurtosis can be used as predictive biomarkers for survival outcomes in patients with high-tumor-burden follicular lymphoma.
Article
Developmental Biology
Kaisa Pakari, Joachim Wittbrodt, Thomas Thumberger
Summary: This article introduces an efficient gene editing method called "inception", which expands the editing range through sequential combinatorial base editing. The applicability of this method is demonstrated in different experimental settings, further expanding the applications of highly precise editing approaches.
Article
Biochemistry & Molecular Biology
Barbara Uhl, Katharina T. Prochazka, Katrin Pansy, Kerstin Wenzl, Johanna Strobl, Claudia Baumgartner, Marta M. Szmyra, James E. Waha, Axel Wolf, Peter Tomazic, Elisabeth Steinbauer, Maria Steinwender, Sabine Friedl, Marc Weniger, Ralf Kueppers, Martin Pichler, Hildegard T. Greinix, Georg Stary, Alan G. Ramsay, Benedetta Apollonio, Julia Feichtinger, Christine Beham-Schmid, Peter Neumeister, Alexander J. Deutsch
Summary: Chemokine receptors and their ligands play an important role in the development of DLBCL, follicular lymphoma, and RS. This study found that the expression profiles of chemokine receptors in de novo DLBCL and tFL were significantly different from that of GC-B and RS. High expression of CCR7 was associated with poor overall survival in patients with de novo DLBCL and tFL.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Review
Radiology, Nuclear Medicine & Medical Imaging
Sally F. Barrington, Farheen Mir, Tarec Christoffer El-Galaly, Andrea Knapp, Tina G. Nielsen, Denis Sahin, Michael Wenger, Lale Kostakoglu, Judith Trotman, Michel Meignan
Summary: Complete metabolic response (CMR) on PET/CT is an independent predictor of overall survival in first-line treatment of high-tumor-burden follicular lymphoma. Patients who do not achieve CMR have poorer outcomes, with those with a Deauville score of 5 showing shorter progression-free survival and time to next treatment than those with a score of 4.
JOURNAL OF NUCLEAR MEDICINE
(2022)
Article
Oncology
Yucai Wang, Shouhao Zhou, Xinyue Qi, Fang Yang, Matthew J. Maurer, Thomas M. Habermann, Thomas E. Witzig, Michael L. Wang, Grzegorz S. Nowakowski
Summary: This study conducted a network meta-analysis to compare the efficacy of different treatment regimens for follicular lymphoma. The results showed that G-Benda-G had the best progression-free survival, indicating that bendamustine is a better chemotherapy backbone for follicular lymphoma.
BLOOD CANCER JOURNAL
(2022)
Article
Biochemistry & Molecular Biology
Kostas Papadopoulos, Kathryn A. Giblin, Jon Paul Janet, Atanas Patronov, Ola Engkvist
Summary: The deep generative model trained with reinforcement learning using 3D shape and pharmacophore similarity scoring component has been shown to efficiently discover new leads in molecular design without relying on other information. Comparison with 2D QSAR models indicates that the 3D similarity based model produces more diverse outputs and allows for scaffold hopping and generation of novel series. Combining the two scoring components for training the generative model leads to more efficient exploration of desirable chemical space.
BIOORGANIC & MEDICINAL CHEMISTRY
(2021)
Article
Medicine, General & Internal
Natasa D. Zdravkovic, Vesna M. Grbovic, Radisa H. Vojinovic, Radojica Stolic, Jelena Z. Zivic, Mladen M. Maksic, Ziva P. Zivic, Nebojsa Andjelkovic, Milos Z. Zivic, Zeljko D. Todorovic
Summary: Follicular lymphoma is the most common indolent non-Hodgkin's lymphoma and is usually initially detected in lymph nodes. We present one unusual case of ileum FL with ascites as the first clinical sign.
MEDICINA-LITHUANIA
(2022)
Article
Medicine, General & Internal
Francois Godard, Eric Durot, Carole Durot, Christine Hoeffel, Alain Delmer, David Morland
Summary: The value of the cerebellum/liver index (CLIP) as a new prognostic marker in pretherapeutic F-18-Fluorodeoxyglucose positron emission tomography (F-18-FDG PET) was investigated in patients with follicular lymphoma. The study found that a higher CLIP value was associated with better progression-free survival (PFS). CLIP could serve as a predictive marker for PFS in follicular lymphoma patients.
Article
Genetics & Heredity
Yuxiang Jiang, Jorge Urresti, Kymberleigh A. Pagel, Akula Bala Pramod, Lilia M. Iakoucheva, Predrag Radivojac
Summary: This study integrates tissue-specific molecular profiles with genetic data to accurately prioritize autism risk genes based on gene co-expression networks and protein-protein interaction networks. By calibrating gene and variant scores, the approach effectively discriminates among variants between cases and controls, contributing to a better understanding of the functional impact of exonic variation in ASD pathogenesis.
Article
Oncology
Rocio Diaz Acedo, Silvia Artacho Criado, Eduardo Rios Herranz, Antonio Gutierrez Pizarraya, Irene Sanchez Romero, Esther Marquez Saavedra
Summary: This study aims to estimate the incidence, severity, and clinical consequences of hypogammaglobulinemia in patients with follicular lymphoma after front-line immunotherapy, and to explore possible predictive factors. The study found that 76.5% of patients had hypogammaglobulinemia during or after front-line treatment, mostly grade 1-2, with 38.8% of patients experiencing clinically relevant infections and 20% requiring human immunoglobulin replacement therapy. A high-risk FLIPI score was identified as a risk factor for hypogammaglobulinemia, while basal gamma globulins level was a protective factor. Any type of immunochemotherapy regimen was associated with different risks of hypogammaglobulinemia in our study.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE
(2023)
Article
Oncology
Eugene Kim, Yanwen Jiang, Tao Xu, Alexandra Bazeos, Andrea Knapp, Christopher R. Bolen, Kathryn Humphrey, Tina G. Nielsen, Elicia Penuel, Joseph N. Paulson
Summary: This study applied non-negative matrix factorization (NMF) and targeted sequencing data to analyze DLBCL, and found that different mutation clusters are associated with clinical prognosis. Specifically, improved overall survival was observed in the BCL2/EZH2 group, which received venetoclax therapy.
Review
Hematology
David Sermer, Pavania Elavalakanar, Jeremy S. Abramson, M. Lia Palomba, Gilles Salles, Jon Arnason
Summary: CD19 is widely present on B-lymphocytes and B-cell malignancies. CD19-directed CAR T cells have improved outcomes in B-cell malignancies, but there are limitations. CD19 can also be targeted by other drugs, but optimal patient selection and sequencing are not established. This review focuses on CD19 as a target for DLBCL treatment, discussing clinical trials of tafasitamab, loncastuximab tesirine, and blinatumo-mab, and the potential of re-challenging with anti-CD19 therapies post-CAR T cells.
Article
Oncology
Olivier Hermine, Linmiao Jiang, Jan Walewski, Andre Bosly, Catherine Thieblemont, Michal Szymczyk, Christiane Pott, Gilles Salles, Pierre Feugier, Kai Hubel, Corinne Haioun, Rene Olivier Casasnovas, Christian Schmidt, Kamal Bouabdallah, Vincent Ribrag, Lothar Kanz, Jan Durig, Bernd Metzner, David Sibon, Morgane Cheminant, Barbara Burroni, Wolfram Klapper, Wolfgang Hiddemann, Michael Unterhalt, Eva Hoster, Martin Dreyling
Summary: Clinical Trial Updates provide an opportunity to disseminate additional results from studies for which the primary end point has already been reported. This study confirms the previously observed substantially prolonged time to treatment failure and shows an improvement in overall survival for patients with Mantle Cell Lymphoma. Some patients with MCL may be cured.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Ana Alarcon Tomas, Joshua A. Fein, Shalev Fried, Jessica R. Flynn, Sean M. Devlin, Warren B. Fingrut, Theodora Anagnostou, Anna Alperovich, Nishi Shah, Ellen Fraint, Richard J. Lin, Michael Scordo, Connie Lee Batlevi, Michal J. Besser, Parastoo B. Dahi, Ivetta Danylesko, Sergio Giralt, Brandon S. Imber, Elad Jacoby, Meirav Kedmi, Arnon Nagler, M. Lia Palomba, Mikhail Roshal, Gilles A. Salles, Craig Sauter, Noga Shem-Tov, Avichai Shimoni, Joachim Yahalom, Ronit Yerushalmi, Gunjan L. Shah, Abraham Avigdor, Miguel-Angel Perales, Roni Shouval
Summary: Persistence or recurrence of large B-cell lymphoma after CD19-CAR-T is common and associated with poor prognosis. Novel agents such as polatuzumab and lenalidomide may have potential as treatment options.
Letter
Oncology
David Qualls, Ariela Noy, David Straus, Matthew Matasar, Craig Moskowitz, Venkatraman Seshan, Ahmet Dogan, Gilles Salles, Anas Younes, Andrew D. Zelenetz, Connie Lee Batlevi
LEUKEMIA & LYMPHOMA
(2023)
Review
Cell Biology
Mostafa Ejtehadifar, Sara Zahedi, Paula Gameiro, Jose Cabecadas, Maria Gomes da Silva, Hans C. Beck, Ana Sofia Carvalho, Rune Matthiesen
Summary: Mass spectrometry-based proteomics has identified proteins as diagnostic, prognostic, and druggable targets in diffuse large B cell lymphoma. We reviewed these studies and extracted the most consistently significantly regulated proteins, including interferon regulatory factor4, annexinA5, and nucleobindin1.
Article
Hematology
Kai Rejeski, Marion Subklewe, Mahmoud Aljurf, Emmanuel Bachy, Adriana Balduzzi, Pere Barba, Benedetto Bruno, Reuben Benjamin, Matteo G. Carrabba, Christian Chabannon, Fabio Ciceri, Paolo Corradini, Julio Delgado, Roberta Di Blasi, Raffaella Greco, Roch Houot, Gloria Iacoboni, Ulrich Jager, Marie Jose Kersten, Stephan Mielke, Arnon Nagler, Francesco Onida, Zinaida Peric, Claire Roddie, Annalisa Ruggeri, Fermin Sanchez-Guijo, Isabel Sanchez-Ortega, Dominik Schneidawind, Maria-Luisa Schubert, John A. Snowden, Catherine Thieblemont, Max Topp, Pier Luigi Zinzani, John G. Gribben, Chiara Bonini, Anna Sureda, Ibrahim Yakoub-Agha
Summary: This study aimed to establish consensus on the grading and management of immune effector cell-associated hematotoxicity (ICAHT) after CAR T-cell therapy. The study found considerable heterogeneity in current practice patterns. Through discussions among an international panel of experts, best practice recommendations were developed. ICAHT was proposed as a novel toxicity category and a framework for its grading, diagnostic workup, and short-and long-term management was provided.
Editorial Material
Hematology
Eric Durot, Alain Delmer
Summary: The Rory Morrison Registry for Waldenstrom Macroglobulinaemia is a UK registry that documents the significant changes in treatments for the rare disease in recent years.
BRITISH JOURNAL OF HAEMATOLOGY
(2023)
Article
Oncology
Dipti Talaulikar, Cecile Tomowiak, Elise Toussaint, Pierre Morel, Prashant Kapoor, Jorge J. Castillo, Alain Delmer, Eric Durot
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
(2023)
Article
Oncology
Guillaume Cartron, Emmanuel Bachy, Herve Tilly, Nicolas Daguindau, Gian-Matteo Pica, Fontanet Bijou, Christiane Mounier, Aline Clavert, Gandhi Laurent Damaj, Borhane Slama, Olivier Casasnovas, Roch Houot, Krimo Bouabdallah, David Sibon, Olivier Fitoussi, Nadine Morineau, Charles Herbaux, Thomas Gastinne, Luc-Matthieu Fornecker, Corinne Haioun, Vincent Launay, Carla Araujo, Omar Benbrahim, Laurence Sanhes, Remy Gressin, Hugo Gonzalez, Franck Morschhauser, David Ternant, Luc Xerri, Karin Tarte, Delphine Pranger
Summary: Rituximab improves progression-free survival and time to next treatment for patients with low-tumor burden follicular lymphoma. However, prolonged maintenance may raise concerns about resources use and patient adhesion. This study investigates the use of short rituximab maintenance using the subcutaneous route.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Serena Zheng, Kanika Gupta, Piyush Goyal, Reiko Nakajima, Laure Michaud, Connie Lee Batlevi, Paul A. Hamlin, Steven Horwitz, Anita Kumar, Matthew J. Matasar, Alison J. Moskowitz, Craig H. Moskowitz, Ariela Noy, M. Lia Palomba, David J. Straus, Gottfried Von Keudell, Lorenzo Falchi, Joachim Yahalom, Andrew D. Zelenetz, Anas Younes, Gilles Salles, Heiko Schoeder, Erel Joffe
Summary: This study discusses the limitations of using interim PET for decision-making and prognosis in the frontline management of Hodgkin's lymphoma. It presents data suggesting that patients who continue treatment with ABVD despite not achieving a complete metabolic response on interim PET may have better outcomes than previously thought. The study also compares the performance of different methods for evaluating PET positivity. Overall, the results indicate that a subset of patients can continue ABVD treatment without a poor outcome, regardless of the criteria for PET2 positivity.
Article
Oncology
Laurence Brugieres, Nathalie Cozic, Roch Houot, Charlotte Rigaud, David Sibon, Julia Arfi-Rouche, Pierre Bories, Anne S. Cottereau, Alain Delmer, Stephane Ducassou, Nathalie Garnier, Laurence Lamant, Amaury Leruste, Frederic Millot, S. Moalla, Franck Morschhauser, Marie Nolla, Anne Pagnier, Yves Reguerre, Loic Renaud, Anne Schmitt, Mathieu Simonin, Arnaud Verschuur, Nathalie Hoog Labouret, Celine Mahier Ait Oukhatar, Gilles Vassal
Summary: The study examined the safety and efficacy of crizotinib in ALK-positive anaplastic large-cell lymphoma (ALK+ ALCL) patients, showing that crizotinib is effective in relapsed/refractory patients, but a large proportion experience relapse after discontinuation. Rating: 8/10.
EUROPEAN JOURNAL OF CANCER
(2023)
Article
Oncology
Marie Balsat, Vincent Alcazer, Gabriel Etienne, Francoise Huguet, Marc Berger, Emilie Cayssials, Aude Charbonnier, Martine Escoffre-Barbe, Hyacinthe Johnson-Ansah, Laurence Legros, Lydia Roy, Alain Delmer, Jean-Christophe Ianotto, Corentin Orvain, Fabrice Larosa, Mathieu Meunier, Shanti Ame, Annalisa Andreoli, Pascale Cony-Makhoul, Stephane Morisset, Isabelle Tigaud, Delphine Rea, Franck Emmanuel Nicolini
Summary: This retrospective study observed the clinical data of newly diagnosed accelerated phase chronic myeloid leukemia (AP-CML) patients who received second-generation tyrosine kinase inhibitors (TKI2) as first-line treatment. The results showed that TKI2 could effectively improve the survival and treatment response of patients.
Correction
Biochemistry & Molecular Biology
Roch Houot, Emmanuel Bachy, Guillaume Cartron, Francois-Xavier Gros, Franck Morschhauser, Lucie Oberic, Thomas Gastinne, Pierre Feugier, Remy Dulery, Catherine Thieblemont, Magalie Joris, Fabrice Jardin, Sylvain Choquet, Olivier Casasnovas, Gabriel Brisou, Morgane Cheminant, Jacques-Olivier Bay, Francisco Llamas Gutierrez, Cedric Menard, Karin Tarte, Marie-Helene Delfau, Cedric Portugues, Emmanuel Itti, Xavier Palard-Novello, Paul Blanc-Durand, Yassine Al Tabaa, Clement Bailly, Camille Laurent, Francois Lemonnier
Article
Biochemistry & Molecular Biology
Roch Houot, Emmanuel Bachy, Guillaume Cartron, Francois-Xavier Gros, Franck Morschhauser, Lucie Oberic, Thomas Gastinne, Pierre Feugier, Remy Dulery, Catherine Thieblemont, Magalie Joris, Fabrice Jardin, Sylvain Choquet, Olivier Casasnovas, Gabriel Brisou, Morgane Cheminant, Jacques-Olivier Bay, Francisco Llamas Gutierrez, Cedric Menard, Karin Tarte, Marie-Helene Delfau, Cedric Portugues, Emmanuel Itti, Xavier Palard-Novello, Paul Blanc-Durand, Yassine Al Tabaa, Clement Bailly, Camille Laurent, Francois Lemonnier
Summary: The study showed that axicabtagene ciloleucel as a second-line therapy was effective and safe for patients with high-risk large B cell lymphoma who could not undergo autologous stem cell transplantation.
Article
Hematology
Ana Carolina Freitas, Tiago Maia, Joana Desterro, Francesca Pierdomenico, Albertina Nunes, Isabelina Ferreira, Jose Cabecadas, Maria Gomes da Silva
Summary: Myelodysplastic/myeloproliferative neoplasms (MDS/MPN) are a diverse group of diseases that are increasingly classified based on recurrent genetic abnormalities. Chromosomal translocations involving meningioma 1 (MN1) and ETS variant 6 (ETV6) genes are rare but common in myeloid neoplasms. We present a case of MDS/MPN with neutrophilia that developed an extramedullary T-lymphoblastic crisis with the t(12;22)(p13;q12) translocation as the only cytogenetic abnormality. This case shares characteristics with myeloid/lymphoid neoplasms with eosinophilia and highlights the importance of molecular characterization in classification and prognostic stratification.
HEMATOLOGY REPORTS
(2023)